Friday, 16 October 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 25, 2026

Michael Saylor Hits 100 Bitcoin Buys—And He's Not Stopping Despite A $7 Billion Loss

View original at finance.yahoo.com
Michael Saylor Hits 100 Bitcoin Buys—And He's Not Stopping Despite A $7 Billion Loss Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Immersed app is the most widely used productivity app on the Meta Quest platform

    80% confidence
  • Celebrated the 100th Bitcoin purchase disclosure milestone since company began accumulating in August 2020

    80% confidence
  • If $105-$110 critical support fails, stock enters true price discovery with next support potentially at $90, then $75, or lower

    80% confidence
  • BAM Capital has completed over $1.85 billion in transactions

    80% confidence
  • The buying will continue regardless of Bitcoin's price trajectory based on Strategy's $7.84 billion available under common stock ATM facility and billions more across preferred stock series

    80% confidence
  • Elf Labs achieved valuation growth exceeding 1,600% in under two years

    80% confidence
  • Breaking below $120 on daily close will likely accelerate toward retesting $105-$110 support level

    80% confidence
  • Elf Labs has generated over $15 million in royalties and expanded licensing into 30+ countries with 100+ product lines

    80% confidence
  • Paladin Power has generated $185 million in contracted revenue and achieved strong year-over-year growth since 2023 launch

    80% confidence

Data points we hold from this source

Strategy · bitcoin average price76020 USD
Elf Labs · trademark portfolio size500 trademarks
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com